Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat < sup > ® < /sup > to the treatment of asthma in adults aged 18 years and over

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat < sup > ® < /sup > to the treatment of asthma in adults aged 18 years and over
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news